Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR

Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR

This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy. We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to Augu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget 2018-01, Vol.9 (6), p.7175-7181
Hauptverfasser: Fang, Shencun, Zhang, Meiling, Wei, Guihong, Lu, Kai-Hua
Format: Artikel
Sprache:eng
Schlagworte:
Clinical Research Paper
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7181
container_issue 6
container_start_page 7175
container_title Oncotarget
container_volume 9
creator Fang, Shencun
Zhang, Meiling
Wei, Guihong
Lu, Kai-Hua
description This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy. We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016. Objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and adverse events (AEs) were reveiwed and evaluated. Univariate and multivariate analyses were performed to determine the prognostic factors. 36 patients were evaluable for safety and efficacy. 6 patients obtained partial response, and 21 showed stable disease. The ORR and DCR were 16.7% and 75%, respectively. The median PFS and OS were 4.5 months and 8.2 months, respectively. Prognostic variable for a longer OS was good performance status ( = 0.015). Most adverse reactions were mild or moderate. Apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type due to its better efficacy and tolerable toxicity.
doi_str_mv 10.18632/oncotarget.23612
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5805545</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2007421158</sourcerecordid><originalsourceid>FETCH-LOGICAL-c271t-38fb24accfe19553c35ffb616e30baccd8fb2fb53e3ae1603ecf9c3150a8ed503</originalsourceid><addsrcrecordid>eNpVUU1LAzEQDaJY0f4AL5Kjl9V8bLa7F0GKX1AU_DiHbHbSjWyTmqSK_96otepcZpg3782Dh9AhJSe0rjg79U77pMIc0gnjFWVbaI82ZVMwIfj2n3mExjE-k1yinNSs2UUj1pTVpBHNHurPlypZZ1usIlY49TZ0BfYBm1VIPYQCD9YBTgFUWoBL2Dr8ychjxG829Vh1r8pp6PDtw3Q2xb0KrQ_WzTM6dEV6XwK-uLq8P0A7Rg0Rxuu-j54uLx6n18Xs7upmej4rNJvQVPDatKxUWhugTTavuTCmrWgFnLR53X3iphUcuAJaEQ7aNJpTQVQNnSB8H5196y5X7QI6nY0GNchlsAsV3qVXVv5HnO3l3L9KURMhSpEFjtcCwb-sICa5sFHDMCgHfhUlI2RSMkpFnU_p96kOPsYAZvOGEvkVkvwNSX6FlDlHf_1tGD-R8A8reJJ-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2007421158</pqid></control><display><type>article</type><title>Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Fang, Shencun ; Zhang, Meiling ; Wei, Guihong ; Lu, Kai-Hua</creator><creatorcontrib>Fang, Shencun ; Zhang, Meiling ; Wei, Guihong ; Lu, Kai-Hua</creatorcontrib><description>This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy. We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016. Objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and adverse events (AEs) were reveiwed and evaluated. Univariate and multivariate analyses were performed to determine the prognostic factors. 36 patients were evaluable for safety and efficacy. 6 patients obtained partial response, and 21 showed stable disease. The ORR and DCR were 16.7% and 75%, respectively. The median PFS and OS were 4.5 months and 8.2 months, respectively. Prognostic variable for a longer OS was good performance status ( = 0.015). Most adverse reactions were mild or moderate. Apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type due to its better efficacy and tolerable toxicity.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.23612</identifier><identifier>PMID: 29467959</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Clinical Research Paper</subject><ispartof>Oncotarget, 2018-01, Vol.9 (6), p.7175-7181</ispartof><rights>Copyright: © 2018 Fang et al. 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c271t-38fb24accfe19553c35ffb616e30baccd8fb2fb53e3ae1603ecf9c3150a8ed503</citedby><cites>FETCH-LOGICAL-c271t-38fb24accfe19553c35ffb616e30baccd8fb2fb53e3ae1603ecf9c3150a8ed503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805545/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805545/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29467959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fang, Shencun</creatorcontrib><creatorcontrib>Zhang, Meiling</creatorcontrib><creatorcontrib>Wei, Guihong</creatorcontrib><creatorcontrib>Lu, Kai-Hua</creatorcontrib><title>Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy. We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016. Objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and adverse events (AEs) were reveiwed and evaluated. Univariate and multivariate analyses were performed to determine the prognostic factors. 36 patients were evaluable for safety and efficacy. 6 patients obtained partial response, and 21 showed stable disease. The ORR and DCR were 16.7% and 75%, respectively. The median PFS and OS were 4.5 months and 8.2 months, respectively. Prognostic variable for a longer OS was good performance status ( = 0.015). Most adverse reactions were mild or moderate. Apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type due to its better efficacy and tolerable toxicity.</description><subject>Clinical Research Paper</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVUU1LAzEQDaJY0f4AL5Kjl9V8bLa7F0GKX1AU_DiHbHbSjWyTmqSK_96otepcZpg3782Dh9AhJSe0rjg79U77pMIc0gnjFWVbaI82ZVMwIfj2n3mExjE-k1yinNSs2UUj1pTVpBHNHurPlypZZ1usIlY49TZ0BfYBm1VIPYQCD9YBTgFUWoBL2Dr8ychjxG829Vh1r8pp6PDtw3Q2xb0KrQ_WzTM6dEV6XwK-uLq8P0A7Rg0Rxuu-j54uLx6n18Xs7upmej4rNJvQVPDatKxUWhugTTavuTCmrWgFnLR53X3iphUcuAJaEQ7aNJpTQVQNnSB8H5196y5X7QI6nY0GNchlsAsV3qVXVv5HnO3l3L9KURMhSpEFjtcCwb-sICa5sFHDMCgHfhUlI2RSMkpFnU_p96kOPsYAZvOGEvkVkvwNSX6FlDlHf_1tGD-R8A8reJJ-</recordid><startdate>20180123</startdate><enddate>20180123</enddate><creator>Fang, Shencun</creator><creator>Zhang, Meiling</creator><creator>Wei, Guihong</creator><creator>Lu, Kai-Hua</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180123</creationdate><title>Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR</title><author>Fang, Shencun ; Zhang, Meiling ; Wei, Guihong ; Lu, Kai-Hua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c271t-38fb24accfe19553c35ffb616e30baccd8fb2fb53e3ae1603ecf9c3150a8ed503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Clinical Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Fang, Shencun</creatorcontrib><creatorcontrib>Zhang, Meiling</creatorcontrib><creatorcontrib>Wei, Guihong</creatorcontrib><creatorcontrib>Lu, Kai-Hua</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fang, Shencun</au><au>Zhang, Meiling</au><au>Wei, Guihong</au><au>Lu, Kai-Hua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2018-01-23</date><risdate>2018</risdate><volume>9</volume><issue>6</issue><spage>7175</spage><epage>7181</epage><pages>7175-7181</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy. We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with apatinib from January 2014 to August 2016. Objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and adverse events (AEs) were reveiwed and evaluated. Univariate and multivariate analyses were performed to determine the prognostic factors. 36 patients were evaluable for safety and efficacy. 6 patients obtained partial response, and 21 showed stable disease. The ORR and DCR were 16.7% and 75%, respectively. The median PFS and OS were 4.5 months and 8.2 months, respectively. Prognostic variable for a longer OS was good performance status ( = 0.015). Most adverse reactions were mild or moderate. Apatinib should be recommended as a third- or further- line therapy in advanced NSCLC patients with EGFR wild-type due to its better efficacy and tolerable toxicity.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>29467959</pmid><doi>10.18632/oncotarget.23612</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1949-2553
ispartof Oncotarget, 2018-01, Vol.9 (6), p.7175-7181
issn 1949-2553
1949-2553
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5805545
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central; Free E- Journals
subjects Clinical Research Paper
title Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T01%3A23%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apatinib%20as%20a%20third-%20or%20further-%20line%20treatment%20in%20patients%20with%20advanced%20NSCLC%20harboring%20wild-type%20EGFR&rft.jtitle=Oncotarget&rft.au=Fang,%20Shencun&rft.date=2018-01-23&rft.volume=9&rft.issue=6&rft.spage=7175&rft.epage=7181&rft.pages=7175-7181&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.23612&rft_dat=%3Cproquest_pubme%3E2007421158%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2007421158&rft_id=info:pmid/29467959&rfr_iscdi=true